GSK Plans Lotronex Randomized Withdrawal Study If Drug Is Reintroduced
Executive Summary
GlaxoSmithKline has committed to a randomized withdrawal study for Lotronex if the irritable bowel syndrome agent is allowed back onto the market
You may also be interested in...
GSK Lotronex Risk Management Program Allows For Off-Label Use
GlaxoSmithKline will track prescriptions for Lotronex to gauge use of the irritable bowel syndrome therapy outside of the risk management program
GSK Lotronex Risk Management Program Allows For Off-Label Use
GlaxoSmithKline will track prescriptions for Lotronex to gauge use of the irritable bowel syndrome therapy outside of the risk management program
GSK Lotronex Plan Follows Accutane Model; Relaunch “Months” Away
GlaxoSmithKline's Lotronex risk management program will follow the Accutane model